Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the last
patient has been enrolled in a double-blind, multiple-dose, phase 3
study to evaluate the efficacy and safety of QuickShot ®
Testosterone (QS T) administered subcutaneously once each week to
testosterone-deficient adult males.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its
third quarter 2014 financial results before the market opens on
Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET
(Eastern Time) to discuss the results.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received
written recommendations from the U.S. Food and Drug Administration (FDA)
related to its clinical development program for QuickShot ®
Testosterone (QS T). The recommendations received were in response to
various clinical, CMC (Chemistry, Manufacturing and Controls) and user
study submissions made by the Company through November 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.